EA201890367A1 - Композиции и способы для лиофильных форм наночастиц - Google Patents
Композиции и способы для лиофильных форм наночастицInfo
- Publication number
- EA201890367A1 EA201890367A1 EA201890367A EA201890367A EA201890367A1 EA 201890367 A1 EA201890367 A1 EA 201890367A1 EA 201890367 A EA201890367 A EA 201890367A EA 201890367 A EA201890367 A EA 201890367A EA 201890367 A1 EA201890367 A1 EA 201890367A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- nucleic acid
- compositions
- liophil
- nanoparticles
- rna
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 239000004375 Dextrin Substances 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 abstract 1
- 108091030071 RNAI Proteins 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 235000019425 dextrin Nutrition 0.000 abstract 1
- 229940126534 drug product Drugs 0.000 abstract 1
- 230000009368 gene silencing by RNA Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- -1 saccharide compound Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Настоящее изобретение обеспечивает композиции для получения твердого лиофила одного или более активных агентов на основе нуклеиновых кислот, которые могут быть восстановлены в качестве лекарственного продукта. Композиция может включать водную суспензию липидных наночастиц в фармацевтически приемлемом растворе, где липидные наночастицы инкапсулируют один или более активных агентов на основе нуклеиновых кислот, соединение декстрина и сахаридное соединение. Активными агентами на основе нуклеиновых кислот могут быть РНК-i молекулы, способные опосредовать РНК интерференцию, а также другие РНК и олигонуклеотиды.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562195356P | 2015-07-22 | 2015-07-22 | |
PCT/US2016/043537 WO2017015552A1 (en) | 2015-07-22 | 2016-07-22 | Compositions and methods for nanoparticle lyophile forms |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201890367A1 true EA201890367A1 (ru) | 2018-06-29 |
EA035761B1 EA035761B1 (ru) | 2020-08-06 |
Family
ID=57834582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890367A EA035761B1 (ru) | 2015-07-22 | 2016-07-22 | Композиция для получения лиофильных форм наночастиц и способ получения лиофильных форм наночастиц |
Country Status (23)
Country | Link |
---|---|
US (3) | US10300018B2 (ru) |
EP (1) | EP3324932B1 (ru) |
JP (2) | JP6875373B2 (ru) |
KR (1) | KR20180030698A (ru) |
CN (2) | CN113679689B (ru) |
AU (1) | AU2016297153B2 (ru) |
BR (1) | BR112018001178A2 (ru) |
CA (1) | CA2992849C (ru) |
CY (1) | CY1123984T1 (ru) |
DK (1) | DK3324932T3 (ru) |
EA (1) | EA035761B1 (ru) |
ES (1) | ES2862191T3 (ru) |
HR (1) | HRP20210523T1 (ru) |
HU (1) | HUE053990T2 (ru) |
IL (2) | IL288342B2 (ru) |
LT (1) | LT3324932T (ru) |
MX (1) | MX2018000891A (ru) |
PL (1) | PL3324932T3 (ru) |
PT (1) | PT3324932T (ru) |
RS (1) | RS61607B1 (ru) |
SI (1) | SI3324932T1 (ru) |
TW (1) | TWI732773B (ru) |
WO (1) | WO2017015552A1 (ru) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210069121A1 (en) | 2017-12-12 | 2021-03-11 | Lead Biotherapeutics Ltd | Solid lipid nanoparticle for intracellular release of active substances and method for production the same |
CN108813619A (zh) * | 2018-07-19 | 2018-11-16 | 广州市汉廷食品有限公司 | 一种无公害食品添加剂及其制备工艺 |
BR112021005815A2 (pt) | 2018-09-28 | 2021-06-29 | Nutcracker Therapeutics, Inc. | formulações de nanoparticulas lipídicas compreendendo compostos peptídicos catiônicos lipidados para liberação de ácido nucleico |
PT3880212T (pt) | 2018-11-16 | 2024-02-08 | Nitto Denko Corp | Formulação e métodos de administração de rna de interferência para tumores malignos |
EP4035686A4 (en) * | 2019-09-26 | 2023-11-01 | NOF Corporation | FREEZE DRIED COMPOSITION OF LIPID NANOPARTICLES |
CA3191874A1 (en) * | 2020-08-14 | 2022-02-17 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
WO2023064891A1 (en) | 2021-10-14 | 2023-04-20 | Hemoshear Therapeutics, Inc. | Compositions and methods of treating diseases associated with bile acid transporter |
CN116643056A (zh) * | 2022-02-15 | 2023-08-25 | 厦门万泰凯瑞生物技术有限公司 | 促甲状腺激素受体复合物、试剂盒、制备方法和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4537683A (en) | 1982-02-01 | 1985-08-27 | Rohm And Haas Company | Trihalomethane precursor removal using ion exchange emulsions |
US4537883A (en) | 1982-11-12 | 1985-08-27 | Mead Johnson & Company | Lyophilized cyclophosphamide |
US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
US20040121983A1 (en) | 2002-08-12 | 2004-06-24 | Council Of Scientific And Industrial Research | Method for treating leishmaniasis using methyl-beta-cyclodextrin |
EP1534340B1 (en) * | 2002-09-06 | 2011-11-16 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto |
ATE476964T1 (de) * | 2003-06-04 | 2010-08-15 | Univ Georgetown | Verfahren zur verbesserung der stabilität und der haltbarkeit von liposom-komplexen |
AU2005302255A1 (en) | 2004-10-28 | 2006-05-11 | Alza Corporation | Lyophilized liposome formulations and method |
AU2005306075A1 (en) | 2004-11-19 | 2006-05-26 | Novosom Ag | Improvements in or relating to pharmaceutical compositions for local administration |
US8263117B2 (en) | 2007-02-09 | 2012-09-11 | National University Corporation NARA Institute of Science and Technology | C70-containing liposome, method for producing the same, and use of the same |
TR201906255T4 (tr) * | 2009-12-11 | 2019-05-21 | Pfizer | Terapötik partiküllerin liyofilize edilmesine yönelik stabil formülasyonlar. |
WO2011103150A2 (en) | 2010-02-18 | 2011-08-25 | Cephalon, Inc. | Lyophilized preparations of bendamustine |
WO2011119995A2 (en) * | 2010-03-26 | 2011-09-29 | Cerulean Pharma Inc. | Formulations and methods of use |
CN102018672B (zh) * | 2010-11-29 | 2013-09-18 | 广州朗圣药业有限公司 | 一种水溶性药物的脂质体冻干组合物及其制备方法 |
US9011903B2 (en) * | 2011-06-08 | 2015-04-21 | Nitto Denko Corporation | Cationic lipids for therapeutic agent delivery formulations |
AU2012267578B2 (en) * | 2011-06-08 | 2017-04-20 | Translate Bio, Inc. | Cleavable lipids |
EP2768484B1 (en) | 2011-10-21 | 2019-07-24 | Jazz Pharmaceuticals Research LLC | Lyophilized liposomes |
US9579338B2 (en) * | 2011-11-04 | 2017-02-28 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
RU2647476C2 (ru) * | 2011-11-04 | 2018-03-15 | Нитто Денко Корпорейшн | Способ получения липидных наночастиц для доставки лекарственного средства |
MY164868A (en) | 2012-03-28 | 2018-01-30 | Discovery Lab Inc | Lyophilization of synthetic liposomal pulmonary surfactant |
JP6211054B2 (ja) * | 2012-03-29 | 2017-10-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 脂質誘導される中性ナノ粒子 |
LT3489220T (lt) | 2012-06-08 | 2021-09-27 | Nitto Denko Corporation | Lipidai, skirti terapinėms agento pristatymo vaisto formoms |
US20140271815A1 (en) | 2013-03-15 | 2014-09-18 | Aryo Sorayya | Heat-and freeze-stable vaccines and methods of making and using same |
-
2016
- 2016-07-22 LT LTEP16828602.9T patent/LT3324932T/lt unknown
- 2016-07-22 DK DK16828602.9T patent/DK3324932T3/da active
- 2016-07-22 PT PT168286029T patent/PT3324932T/pt unknown
- 2016-07-22 CN CN202110916430.8A patent/CN113679689B/zh active Active
- 2016-07-22 JP JP2018503253A patent/JP6875373B2/ja active Active
- 2016-07-22 TW TW105123227A patent/TWI732773B/zh active
- 2016-07-22 SI SI201631140T patent/SI3324932T1/sl unknown
- 2016-07-22 CN CN201680054543.9A patent/CN108024957B/zh active Active
- 2016-07-22 RS RS20210355A patent/RS61607B1/sr unknown
- 2016-07-22 WO PCT/US2016/043537 patent/WO2017015552A1/en active Application Filing
- 2016-07-22 HU HUE16828602A patent/HUE053990T2/hu unknown
- 2016-07-22 US US15/217,098 patent/US10300018B2/en active Active
- 2016-07-22 BR BR112018001178A patent/BR112018001178A2/pt active Search and Examination
- 2016-07-22 MX MX2018000891A patent/MX2018000891A/es active IP Right Grant
- 2016-07-22 AU AU2016297153A patent/AU2016297153B2/en active Active
- 2016-07-22 ES ES16828602T patent/ES2862191T3/es active Active
- 2016-07-22 EP EP16828602.9A patent/EP3324932B1/en active Active
- 2016-07-22 KR KR1020187005141A patent/KR20180030698A/ko not_active Application Discontinuation
- 2016-07-22 IL IL288342A patent/IL288342B2/en unknown
- 2016-07-22 EA EA201890367A patent/EA035761B1/ru not_active IP Right Cessation
- 2016-07-22 CA CA2992849A patent/CA2992849C/en active Active
- 2016-07-22 PL PL16828602T patent/PL3324932T3/pl unknown
-
2018
- 2018-01-18 IL IL257029A patent/IL257029B/en unknown
-
2019
- 2019-04-05 US US16/377,032 patent/US11737982B2/en active Active
-
2021
- 2021-03-31 CY CY20211100280T patent/CY1123984T1/el unknown
- 2021-03-31 HR HRP20210523TT patent/HRP20210523T1/hr unknown
- 2021-04-22 JP JP2021072339A patent/JP7268079B2/ja active Active
-
2023
- 2023-06-30 US US18/346,115 patent/US20240000710A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890367A1 (ru) | Композиции и способы для лиофильных форм наночастиц | |
AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
WO2017100236A8 (en) | Methods and compositions for treating a serpinc1-associated disorder | |
WO2015106128A3 (en) | Rnai agents modified at the 4'-c-position | |
CO7310520A2 (es) | Nanopartícula polimérica de finasterida y minoxidil proceso de preparación, suspensión acuosa conteniendo la misma,composición farmaceútica y su uso | |
EA201691448A1 (ru) | Гибридосомы, содержащие их композиции, способы их получения и их применения | |
EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
FR3046792B1 (fr) | Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
MA37206B1 (fr) | Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2017193087A8 (en) | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna | |
TR201901939T4 (tr) | Antisens nükleik asit. | |
BR112015032736A2 (pt) | inibidores de bromodomínio cristalino | |
EA201500383A1 (ru) | Производные 1,2,4-триазина для лечения вирусных инфекций | |
FR3037956B1 (fr) | Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
BR112015000229A2 (pt) | formulações aquosas estáveis de etanercept | |
EA201691293A1 (ru) | Гетероарильные производные бутановой кислоты в качестве ингибиторов lta4h | |
EA201500112A1 (ru) | 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств | |
EA202090720A1 (ru) | ПРОИЗВОДНЫЕ GalNAc | |
WO2016065349A8 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
BR112017004393A2 (pt) | formulações de anticorpo | |
EA201591618A1 (ru) | Замещенные имидазопиридазины | |
EA201790773A1 (ru) | Композиции и способы для ингибирования биологической активности растворимых биомолекул |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |